Impact of rituximab therapy on endothelial function and other markers of atherosclerosisin patients with active rheumatoid arthritis

Endothelial dysfunction plays a key role in the pathogenesis of atherosclerosis. An increased cardiovascular risk in patients with rheumatoid arthritis (RA) suggests that inflammation is of importance for the occurrence and progression of atherosclerosis. Rituximab (RTM, monoclonal antibodies to CD2...

Full description

Bibliographic Details
Published in:	Научно-практическая ревматология
Main Authors:	Aleksandr Vital'evich Volkov, O G Lineva, K Kh Kuzikyants, G V Lukina, E L Nasonov, Aleksandr Vitalyevich Volkov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2010-12-01
Subjects:	rheumatoid arthritis rituximab cardiovascular diseases atherosclerosis endothelial function flow-dependent vasodilation
Online Access:	https://rsp.mediar-press.net/rsp/article/view/953

Similar Items

THE RUSSIAN REGISTRY OF RITUXIMAB. ANALYSIS OF THE EFFICIENCY OF THERAPY AND THE FUNCTIONAL STATEOF PATIENTS WITH RHEUMATOID ARTHRITIS
by: Vera Nikolayevna Amirdzhanova, et al.
Published: (2010-08-01)

ROLE OF MULTIPLEX CYTOKINE ANALYSIS IN THE EVALUATION OF THE EFFICACY OF RITUXIMAB DURING TREATMENT FOR RHEUMATOID ARTHRITIS
by: A. A. Novikov, et al.
Published: (2011-06-01)

THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF ANTI-B-CELL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: Elena Nikolayevna Aleksandrova, et al.
Published: (2012-02-01)

Combination therapy for rheumatoid arthritis with rituximab and leflunomide(preliminary results of the Russian ARBITR Registry)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2011-02-01)

EFFECT OF RITUXIMAB ON THE BLOOD CHOLESTEROL TRANSPORT SYSTEM IN PATIENTSWITH RHEUMATOID ARTHRITIS
by: Tatyana Valentinovna Popkova, et al.
Published: (2010-08-01)

RITUXIMAB THERAPY MONITORING IN PATIENTS WITH RHEUMATOID ARTHRITIS HROUGH PERIPHERAL BLOOD GENE EXPRESSION ANALYSIS
by: E. V. Chetina, et al.
Published: (2014-06-01)

Evaluation of the clinical efficiency of tocilizumab versus rituximab therapy in patients with rheumatoid arthritis
by: Anastasia Sergeyevna Avdeyeva, et al.
Published: (2012-08-01)

Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy
by: A. S. Avdeeva, et al.
Published: (2021-09-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

Administration of monoclonal antibodies to b-lymphocytes (rituximab) in rheumatoid arthritis in Russia
by: E L Nasonov, et al.
Published: (2008-08-01)

Relationship between laboratory biomarkers and ultrasonographic signs of inflammation in patients with rheumatoid arthritis treated with a rituximab biosimilar
by: A. S. Avdeeva, et al.
Published: (2022-06-01)

Tumor necrosis factor-α inhibitors and their effects on cardiovascular risk factorsin patients with rheumatoid arthritis
by: O G Lineva, et al.
Published: (2010-02-01)

IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2018-11-01)

Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations
by: T. S. Panevin, et al.
Published: (2023-10-01)

Ten-year experience with rituximab for induction and maintenance therapy in patients with ANCA-associated systemic vasculitis
by: T. V. Beketova, et al.
Published: (2020-03-01)

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)
by: E. L. Nasonov, et al.
Published: (2016-12-01)

The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis
by: L. P. Ananyeva, et al.
Published: (2023-08-01)

THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL
by: E. L. Nasonov, et al.
Published: (2017-09-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
by: D. A. Kusevich, et al.
Published: (2019-01-01)

Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: Preliminary data
by: O A Logvinenko, et al.
Published: (2012-12-01)

Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2019-07-01)

Dynamics of lymphocyte subpopulations, CD4+CD25+CD127- T regulatory cells in patients with rheumatoid arthritis during therapy with the rituximab biosimilar Acellbia
by: A. S. Avdeeva, et al.
Published: (2020-05-01)

CHANGES IN HEART RATE, HEART RATE VARIABILITY AND QT INTERVAL IN WOMEN WITH RHEUMATOID ARTHRITIS DURING RITUXIMAB TREATMENT
by: D. S. Novikova, et al.
Published: (2014-06-01)

Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland)
by: A. S. Avdeeva, et al.
Published: (2019-03-01)

Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
by: D. A. Kusevich, et al.
Published: (2022-06-01)

RITUXIMAB TREATMENT FOR INTERSTITIAL LUNG INJURY IN SCLERODERMA SYSTEMATICA
by: Lidia Petrovna Ananieva, et al.
Published: (2013-12-01)

Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation
by: L. P. Ananyeva, et al.
Published: (2019-07-01)

Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2020-11-01)

The role of monitoring the level of matrix metalloproteinase 3 in patients with rheumatoid arthritis on anti-B-cell therapy
by: A. S. Avdeeva, et al.
Published: (2022-09-01)

PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS
by: Volkava M. V.
Published: (2019-11-01)

RITUXIMAB TREATMENT EFFICACY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS REFRACTORY TO STANDARD THERAPY IN THE LONG-TERM FOLLOW-UP
by: M. E. Tsanyan, et al.
Published: (2014-06-01)

Rituximab in the treatment of nodal Bcell marginal zone lymphoma, primary Sjogren’s syndrome and autoimmune hepatitis
by: O A Logvinenko, et al.
Published: (2008-10-01)

EFFECT OF RITUXIMAB ON CARDIAC ELECTROPHYSIOLOGICAL PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: L. I. Feiskhanova
Published: (2018-11-01)

The Impact of Rituximab Therapy on the Chromosomes of Patients with Rheumatoid Arthritis
by: Šekib Sokolović, et al.
Published: (2010-05-01)

Experience with long-term infliximab therapy in patients with ankylosing spondylitis
by: Oksana Alekseevna Rumyantseva, et al.
Published: (2010-12-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
by: A V Bezgin, et al.
Published: (2011-08-01)

EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Mikhail Sergeyevich Protopopov, et al.
Published: (2013-02-01)

Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis
by: Hüseyin Demirci, et al.
Published: (2024-10-01)